The Bochum Optimizing Clopidogrel-Aspirin Therapy and MORTality Study (BOCLA-Mort)
Comparing standard treatment versus optimized antiplatelet therapy and outcomes measures.
Coronary Artery Disease
|Study Design:||Observational Model: Case Control
Time Perspective: Retrospective
|Official Title:||Optimized Antiplatelet Therapy With Aspirin and Clopidogrel Improves Mortality Compared to Standard Treatment.|
- Adverse cardiac events (MACE: mortality,rehospitalisation,myocardial infarction) [ Time Frame: Follow up for up to 12 months (retrospective analysis) ] [ Designated as safety issue: No ]MACE-rate
|Study Start Date:||January 2009|
|Study Completion Date:||February 2013|
|Primary Completion Date:||February 2013 (Final data collection date for primary outcome measure)|
Antiplatelet therapy following coronary stenting without platelet function testing
Optimized antiplatelet therapy
Platelet function testing and according to a test and treat strategy improve the antiplatelet therapy in low-responder.
Treatment adjustments were done as published before - see BOCLA-Plan manuscript. (Reference: Tailored antiplatelet therapy can overcome clopidogrel and aspirin resistance--the BOchum CLopidogrel and Aspirin Plan (BOCLA-Plan) to improve antiplatelet therapy. BMC Med. 2011 Jan 12;9:3.)
The study is aimed to evaluate if optimized antiplatelet treatment using a test and treat algorithm (with whole blood aggregometry) is able to improve clinical outcome of patients compared to standard treatment without platelet function testing.
|Cardiovascular Center, Ruhr-University Bochum|
|Bochum, NRW, Germany, D-44791|
|Principal Investigator:||Horst Neubauer, MD||Ruhr-University Bochum, Cardiovascular Center|